Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3702 in Systemic Lupus Erythematosus
NCT06859931Phase 2Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3702 in systemic lupus erythematosus (SLE), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
TQB3702
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06859931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859931.